31 results
8-K
EX-99.1
INVA
Innoviva Inc
24 May 23
Corporate Presentation May 2023
5:18pm
with Entasis’ innovation capabilities and La Jolla’s historically targeted, robust commercial platform Asset differentiation and benefits of scale expected
8-K
EX-99.1
INVA
Innoviva Inc
23 Aug 22
Other Events
4:08pm
, is intended to modernize the regulation of drugs and spur innovation, but not all its provisions have yet been implemented. Additionally, in August 2017 … . On November 20, 2020, CMS issued an interim final rule through the CMS Innovation Center whereby Medicare Part B reimbursement for “certain high-cost
SC TO-C
EX-99.1
ETTX
Entasis Therapeutics Holdings Inc.
23 May 22
Information about tender offer
8:54pm
with significant unmet medical need. Innoviva shares your belief in novel infectious disease therapies as a critical area of innovation and value to patients
SC TO-C
EX-99.3
ETTX
Entasis Therapeutics Holdings Inc.
23 May 22
Information about tender offer
8:54pm
disease as a great opportunity for two reason:
First, anti-infectives innovation is one of the most important priorities for global health and societal
SC TO-C
EX-99.2
i7lzw47fnj87 gb3
23 May 22
Information about tender offer
8:54pm
8-K
EX-99.1
hdxgc
7 Apr 22
Regulation FD Disclosure
5:09pm
8-K
EX-99.1
0zskr
13 Dec 21
Corporate Presentation December 2021
4:39pm